US20060239957A1 - Cosmetic and dermopharmaceutical compositions for skin prone to acne - Google Patents
Cosmetic and dermopharmaceutical compositions for skin prone to acne Download PDFInfo
- Publication number
- US20060239957A1 US20060239957A1 US11/390,710 US39071006A US2006239957A1 US 20060239957 A1 US20060239957 A1 US 20060239957A1 US 39071006 A US39071006 A US 39071006A US 2006239957 A1 US2006239957 A1 US 2006239957A1
- Authority
- US
- United States
- Prior art keywords
- acne
- ppm
- skin
- acid
- oleanolic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 55
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 239000002537 cosmetic Substances 0.000 title claims abstract description 30
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims abstract description 94
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 53
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 53
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 53
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 53
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 52
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 10
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims description 46
- 229960003951 masoprocol Drugs 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 27
- 239000013543 active substance Substances 0.000 claims description 18
- 239000004615 ingredient Substances 0.000 claims description 12
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 7
- 229940124091 Keratolytic Drugs 0.000 claims description 5
- 230000001530 keratinolytic effect Effects 0.000 claims description 5
- 230000003204 osmotic effect Effects 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 39
- 240000007817 Olea europaea Species 0.000 abstract description 27
- 235000002725 Olea europaea Nutrition 0.000 abstract description 26
- 244000122992 Larrea divaricata Species 0.000 abstract description 15
- 235000002828 Larrea divaricata Nutrition 0.000 abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 21
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229960003604 testosterone Drugs 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 241000186427 Cutibacterium acnes Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- -1 sticks and pencils Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- 244000299507 Gossypium hirsutum Species 0.000 description 4
- 241000192087 Staphylococcus hominis Species 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003255 anti-acne Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 241001518260 Corynebacterium minutissimum Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 241000715846 Sibynophis collaris Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 208000029443 keratinization disease Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 229940082862 olea europaea leaf extract Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- Various forms of acne exist. These include: juvenile, which may emerge as of age 9 years, with no premonitory sign of puberty, and which affects approximately 70% of adolescents of both genders; adult, which, outside of the consequences of hormonal contraceptive treatment, corresponds, in fact, in most cases, to juvenile acne persisting in the absence of treatment of after inappropriate treatment; drug-related, the main causes of which are vitamin B12, systemic or local corticosteroids, iodine- or bromine-based preparations, androgens and androgenic progestogen contraceptive pills; neonatal, due to maternal androgens, and for which recovery is spontaneous; excoriated, of young girls, which is an exacerbation of normal and classic juvenile acne due to almost obsessive touching of acne spots.
- the androgen hormone most involved in acne is testosterone.
- Gonadal testosterone circulates in the body in a protein-bound form and only free testosterone enters the target cell: the sebaceous gland.
- an enzyme, 5 ⁇ -reductase converts testosterone to its metabolite, dihydrotestosterone (DHT), which stimulates the synthesis of nuclear proteins.
- DHT dihydrotestosterone
- the more DHT which reaches the nucleus the greater the increase in sebaceous gland size and proliferation.
- the glands fill with lipids and, since the sebaceous gland is a holocrine secretory gland, the greater the quantity of excreted sebum.
- the microcyst can then evolve in 2 ways: either the keratin and sebum continue to provoke swelling of the microcyst forcing dilation of the acro-infundibulum, thus forming an open comedo or common blackhead, with no real seriousness; or the wall of the microcyst ruptures with irruption into the dermis of sebum, keratin and free fatty acids. An inflammatory reaction occurs, which is exacerbated by the last component in the etiology of acne.
- a yeast Pityrosporum ovale, whose pathogenic role in acne appears nil, a non-pathogenic white Staphylococcus, an anaerobic bacteria, diphtheroid and Gram-positive: Corynebacterium acnes (formerly called Propionibacterium acnes ), which synthesizes a lipase able to hydrolyze the triglycerides of sebum into free fatty acids that are irritants for the dermis.
- This microorganism is also involved in the local production of protease, hyaluronidase and neuraminidase, which exacerbate the inflammatory process cited above.
- the present invention includes the use of oleanolic acid, pure or isolated or contained in titrated olive tree ( Olea europaea ) leaf extract in an effective and/or sufficient quantity, in a cosmetic or dermopharmaceutical composition. These compositions may be intended to prevent and treat the symptoms of acne, hyperseborrhea and acne-prone skin.
- the oleanolic acid, whether as part of an extract or otherwise may be used along with an effective and/or sufficient quantity of nordihydroguaiaretic acid (pure or isolated or in the form of a titrated Larrea divaricata extract).
- Cosmetic or dermopharmaceutical compositions intended to prevent and treat the symptoms of acne, hyperseborrhea and to prevent symptoms in acne-prone skin containing an effective and sufficient quantity of oleanolic acid or titrated Olea europaea leaf extract containing it.
- These cosmetic or dermopharmaceutical compositions may also contain an effective and/or sufficient quantity of nordihydroguaiaretic acid or a titrated Larrea divaricata extract containing it.
- the quantity of oleanolic acid is between 1 and 10,000 ppm (0.0001 and 1% m/m), preferably between 10 and 1000 ppm (0.001 and 0.1% m/m).
- the quantity of nordihydroguaiaretic acid is, if present, between 1 and 10,000 ppm (0.0001 and 1% m/m), preferably between 10 and 1000 ppm (0.001 and 0.1% m/m).
- a particularly preferred cosmetic and/or dermopharmaceutical composition includes a concentration of the oleanolic acid (used pure or in the form of Olea europaea extract) of between 5 and 50 ppm (0.0005 to 0.05% m/m) and a concentration of nordihydroguaiaretic acid (used pure or in the form of titrated Larrea divaricata extract) of between 1 and 100 ppm (0.0001 to 0.01% m/m).
- Cosmetic or dermopharmaceutical compositions may include any other ingredient usually employed in the fields of cosmetics and dermopharmacy. These can include, without limitation, lipids including extracted and/or synthetic lipids, gelling and viscosifying polymers, surfactants and emulsifying agents, any water- or fat-soluble active substance, plant extracts of all sorts, synthetic peptides, proteins, vitamins, tissue extracts, marine extracts, sunscreens and antioxidants.
- a particularly preferred composition includes OSMOCIDE® (marketed by the Sederma company, France).
- compositions may be combined with other active substances and may be used in any pharmaceutical form employed in cosmetics or dermopharmacy such as, without limitation, gels, O/W and W/O emulsions, milks, lotions, ointments, scalp lotions, shampoos, soaps, sticks and pencils, sprays and body oils.
- the active substances may be used in the form of a solution, dispersion or emulsion, or encapsulated in carriers such as macro-, micro- or nanocapsules, liposomes or chylomicrons, or included in macro-, micro- or nanoparticles, or in microsponges, or adsorbed on powdered organic polymers, talcs, bentonites and other inorganic carriers.
- carriers such as macro-, micro- or nanocapsules, liposomes or chylomicrons, or included in macro-, micro- or nanoparticles, or in microsponges, or adsorbed on powdered organic polymers, talcs, bentonites and other inorganic carriers.
- Oleanolic acid pure or in the form of titrated olive tree ( Olea europaea ) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract), or combined with other active substances can be used for the preparation of a medicinal product used for any form of moisturizing or anti-inflammatory care of the skin and in the prevention and treatment of acne-prone skin.
- the cosmetic or dermopharmaceutical compositions of the invention may have the active substances impregnated on any sort of textile, synthetic or natural fiber, wool or any material liable to be used for the manufacture of clothing or underclothing, active materials of any sort, wipes, patches, compresses, cottons, cotton buds, dressings, makeup-removal sponges, masks and any other carrier liable to come into direct contact with the skin or scalp to enable continuous topical delivery.
- oleanolic acid and extracts of olive tree are endowed with a strong inhibitory action on the enzyme, 5 ⁇ -reductase, and thus constitute an important component in the treatment of the symptoms of acne-prone skin.
- oleanolic acid and the extracts of olive tree leaves are endowed with antimicrobial activity against Corynebacterium acnes and Acinetobacter calcoaceticus. The use of oleanolic acid and olive leaf extracts to prevent and treat the symptoms of acne and acne-prone skin is thus new.
- Nordihydroguaiaretic acid is an inhibitor of protein metabolism in the Golgi apparatus and thus plays a moderating role in cell growth.
- the use of nordihydroguaiaretic acid to slow the growth of the skin and appendages has been described in FR 2785804. It appears that combination of oleanolic acid and nordihydroguaiaretic acid or extracts containing those compounds strengthens the antimicrobial activity and decreases hyperkeratinization concomitantly, thus enhancing prevention of the symptoms of acne.
- Anti-acne activity can be further reinforced if the cosmetic and dermopharmaceutical compositions containing said extracts are formulated with other appropriate compounds such as keratolytic, sebum-regulating, moisturizing and/or osmotic active substances (particularly those with specific antimicrobial and anti-inflammatory activities).
- compositions may be any habitually or newly used or usable ingredient in cosmetics and dermopharmacy.
- Oleanolic acid combined or not combined with nordihydroguaiaretic acid and/or the plant extracts containing them may thus be advantageously used in the prevention and treatment of acne-prone skin since: oleanolic acid decreases hyperseborrhea by inhibiting 5 ⁇ -reductase and nordihydroguaiaretic acid (NDGA) exerts an anti-inflammatory and antiproliferative effect on keratinocytes and reduces hyperkeratinization.
- NDGA nordihydroguaiaretic acid
- compositions it may be advantageous to combine the extracts cited with other active substances in order to strengthen their effect by an additive or synergistic effect of the various products or in order to combine the effect described in this patent application with another beneficial physiological effect for the skin, mucous membranes, cutaneous appendages (hair and scalp), such as OSMOCIDE® (Sederma).
- the oleanolic acid and, possibly, nordihydroguaiaretic acid concentrations in the cosmetic or dermopharmaceutical product may vary from 1 to 10,000 ppm (0.0001 and 1%, m/m), preferably between 10 and 1000 ppm (0.001 and 0.1% m/m).
- ppm 0.0001 and 1%, m/m
- ppm 0.0005 to 0.05% m/m
- ppm 0.0001 to 0.01% m/m
- divaricata used in the finished products depend on their respective oleanolic acid and nordihydroguaiaretic acid contents.
- the final concentrations of the main active substances are to lie within the ranges cited.
- Oleanolic acid pure or in the form of titrated olive tree ( Olea europaea ) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract) or combined with other active substances, may be used in any pharmaceutical form employed in cosmetics or dermopharmacy: O/W and W/O emulsions, milks, lotions, ointments, scalp lotions, shampoos, soaps, sticks and pencils, sprays and body oils, without that list being exhaustive.
- Oleanolic acid pure or in the form of titrated olive tree ( Olea europaea ) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract), or combined with other active substances, may be used in the form of solutions, dispersions and emulsions, or encapsulated in carriers such as macro-, micro- or nanocapsules and liposomes or chylomicrons, or included in macro-, micro- or nanoparticles or in microsponges, or adsorbed on powdered organic polymers, talcs, bentonites or other inorganic carriers.
- Oleanolic acid pure or in the form of titrated olive tree ( Olea europaea ) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract) may be combined with any other usually employed ingredient: extracted and/or synthetic lipids, gelling and viscosifying polymers, surfactants and emulsifying agents, all water- and fat-soluble active substances, plant extracts of any sort, synthetic peptides, proteins, vitamins, tissue extracts, marine extracts, sunscreens and antioxidants.
- Oleanolic acid pure or in the form of titrated olive tree ( Olea europaea ) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract) or combined with other active substances, may be used in cosmetic or dermopharmaceutical compositions for all skin care, moisturizing or anti-inflammatory, and in the prevention and treatment of acne-prone skin.
- Oleanolic acid pure or in the form of titrated olive tree ( Olea europaea ) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract) or combined with other active substances, may be incorporated in cosmetic compositions or dermopharmaceuticals for the preparation of medicinal products used in moisturizing or anti-inflammatory care of the skin and in the prevention and treatment of acne-prone skin.
- Oleanolic acid pure or in the form of titrated olive tree ( Olea europaea ) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract), or combined with other active substances, may be used to impregnate any sort of textile, synthetic or natural fibers, wool or any materials liable to be used for the manufacture of clothing or underclothing, active materials of any sort, wipes, patches, compresses, cottons, and cotton buds, dressings, makeup-removing sponges, masks, or any other carrier liable to come into direct contact with the skin and scalp to enable continuous topical delivery.
- Examples 1 to 4 illustrate the various possibilities for compositions intended for cosmetic or dermopharmaceutical uses containing oleanolic acid and/or nordihydroguaiaretic acid or the corresponding extracts.
- Examples 5 to 10 illustrate the effects of those compositions and the synergistic effects observed with combination of the various constituents.
- Carbopol ® 1342 (Goodrich) 0.3 Propylene glycol 2 Glycerol 1 White soft paraffin 1.5 Cyclomethicone 6 Cetyl alcohol 0.5 Lubrajel ® MS (United Guardian) 10 Triethanolamine 0.3 Oleanolic acid 0.0015 Nordihydroguaiaretic acid 0.002 Osmocide ® (Sederma) 9.0 Water, preservatives, fragrance q.s. 100 g
- Testosterone is irreversibly metabolized by 5 ⁇ -reductase to 5-dehydrotestosterone (5-DHT) in the presence of the cofactor NADPH.
- the reaction is monitored, at 37° C., by determining, using a spectrophotometer, the reduction in the absorbance of the reaction medium at 340 nm, due to the conversion of NADPH to NADP.
- the test thus consists in mixing testosterone, NADPH and the test product or its vehicle alone (control reaction). After 3 minutes to allow the system to equilibrate, the baseline absorbance of the system is determined. Then the reaction is triggered by addition of the enzyme, 5 ⁇ -reductase. After 10 minutes, a second determination of the absorbance, final absorbance, is conducted. The difference between the two measurements reflects the quantity of NADPH consumed. That quantity is proportional to the quantity of testosterone converted to 5-DHT.
- Oleanolic acid and nordihydroguaiaretic acid were tested at various concentrations alone or in combination.
- testosterone absorbs light at the wavelength used (245 nm).
- the decrease in testosterone peak area (which was characterized under our operating conditions by a retention time of 26 minutes) reflects the reduction of the concentration of the compound in the study medium and thus reflects 5 ⁇ -reductase activity.
- reaction media were analyzed by HPLC.
- Results the following table shows the percentage inhibition (mean ⁇ SEM) observed in 5 independent assays.
- oleanolic acid is endowed with strong inhibitory activity vis-à-vis the enzyme, 5 ⁇ -reductase, since, under our experimental conditions, 48% inhibition was observed with only 0.1% oleanolic acid. Nordihydroguaiaretic acid used alone had no activity in this test;
- IL-6 interleukin 6
- HF normal human fibroblasts
- HK keratinocytes
- the cells were cultured in a conventional culture medium (DMEMc+10% FCS) for periods of 24 hours for HF and 1 week for HK. After elimination of the buffer and 2 successive washings with phosphate buffer solution, the cells were exposed to UV-B irradiation at a standardized energy level of 50 mJ.cm ⁇ 2 .
- DMEMc+10% FCS a conventional culture medium
- FCS phosphate buffer solution
- the buffer was then rapidly eliminated and replaced by the same culture medium as that used at the start of the experiment, but containing the test extracts at the prerequisite concentrations or DMSO for the control series. After 24 hours, the culture medium was harvested and IL-6 concentration determined using a standard ELISA method.
- nordihydroguaiaretic acid has a remarkable anti-inflammatory effect on the 2 cell lines studied since, under our experimental conditions (HF and HK), inhibition of 19% (+356 vs. +439%) and 14% (+388 vs. +450%) was observed with a nordihydroguaiaretic acid concentration of only 0.01%. Moreover, the effect was specific, since it was concentration-dependent;
- oleanolic acid used alone is devoid of activity in this test
- HK normal human keratinocytes
- DMEMc+10% FCS classic culture medium
- test product control series in order to determine the baseline cell proliferation of the system studied
- test products alone or in combination.
- Fluorophore Hoechst 33258 was added at the end of the protocol before withdrawing cell aliquots for assay.
- the assays were conducted in triplicate as 3 mutually independent assays.
- Results the following table shows the percentage inhibition (mean ⁇ SEM) with respect to the quantities of DNA (and hence the number of cells present, as observed in each of the 5 independent assays).
- Test product [c] % inhibition Oleanolic acid 0.01% 0.9 ⁇ 1.0% 0.03% 1.1 ⁇ 1.6% 0.1% 0.7 ⁇ 0.7% NDGA 0.01% 10.2 ⁇ 1.5% 0.04% 22.3 ⁇ 1.9% 0.1% 29.9 ⁇ 1.7% Oleanolic acid + 0.03% nordihydroguaiaretic acid 0.04% 41.7 ⁇ 3.4%
- nordihydroguaiaretic acid strongly inhibits keratinocyte proliferation since, under our experimental conditions, 10% inhibition was observed with a concentration of only 0.01% nordihydroguaiaretic acid. Moreover, the effect was specific since it was concentration-dependent;
- Results The following table shows the observed antimicrobial activity results for the constituents and their combination in the cosmetic excipient.
- Oleanolic acid exerted selective antimicrobial activity against the microorganisms P. acnes and A. calcoaceticus. Nordihydroguaiaretic acid exerted selective antimicrobial activity against A. calcoaceticus and S. hominis. OSMOCIDE® exerted selective antimicrobial activity against S. aureus, S. hominis and P. acnes, while none of the other constituents showed any effect.
- Strain C Staphylococcus aureus
- test product the gel in example No. 2
- All other products topical medication, cosmetic or dermatological products were prohibited throughout the duration of the study.
- the lesions were counted and observed by dermatologists, on the same predetermined area of the facial skin (20 cm 2 ), pre-treatment (T0) and after 30 (T30) and 60 (T60) days of treatment. A significant decrease in the lesions and a marked improvement in the state of the face were observed after the cosmetic treatment. The product did not induce irritation, edema or other signs of poor tolerance.
Abstract
The invention relates to the use of an extract of olive leaves (Olea europaea) which is titrated in oleanolic acid and which may or may not be associated with a Larrea divaricata extract which is titrated in nordihydroguaiaretic acid (NDGA). Said products are intended for all types of cosmetic and dermopharmaceutical compositions for all forms of skin care, for moisturizing and anti-inflammatory purposes and, in particular, for the prevention and treatment of skin prone to acne.
Description
- This application is a divisional of U.S. application Ser. No. 10/817,670, filed on Apr. 2, 2004, which is a continuation-in-part of PCT Patent Application No. PCT/FR 02/03344, designating the U.S., filed Oct. 1, 2002, which was published in French, which claims priority from French Patent Application No. FR 01/12802, filed Oct. 3, 2001, the disclosures of which are incorporated herein by reference.
- Various forms of acne exist. These include: juvenile, which may emerge as of age 9 years, with no premonitory sign of puberty, and which affects approximately 70% of adolescents of both genders; adult, which, outside of the consequences of hormonal contraceptive treatment, corresponds, in fact, in most cases, to juvenile acne persisting in the absence of treatment of after inappropriate treatment; drug-related, the main causes of which are vitamin B12, systemic or local corticosteroids, iodine- or bromine-based preparations, androgens and androgenic progestogen contraceptive pills; neonatal, due to maternal androgens, and for which recovery is spontaneous; excoriated, of young girls, which is an exacerbation of normal and classic juvenile acne due to almost obsessive touching of acne spots.
- Thus, most forms of acne derive more or less directly from juvenile acne. Acne is, in all likelihood, a multifactorial disease which can be summarized by the following triad: hyperseborrhea+disorder of keratinization of the pilosebaceous canal+a microbial factor.
- Hyperseborrhea
- There is no acne without hyperseborrhea and, broadly speaking, acne is proportional to the degree of seborrhea. Sebum secretion is under hormonal control and constitutes one of the best indicators of androgen levels explaining the emergence of acne at the time of puberty, during which a physiological hormonal explosion occurs.
- The androgen hormone most involved in acne is testosterone. Gonadal testosterone circulates in the body in a protein-bound form and only free testosterone enters the target cell: the sebaceous gland. There, an enzyme, 5α-reductase, converts testosterone to its metabolite, dihydrotestosterone (DHT), which stimulates the synthesis of nuclear proteins. The more DHT which reaches the nucleus, the greater the increase in sebaceous gland size and proliferation. The glands fill with lipids and, since the sebaceous gland is a holocrine secretory gland, the greater the quantity of excreted sebum.
- Keratinization Disorder of the Pilosebaceous Canal
- This point constitutes a sine qua non condition for the occurrence of acne. The epithelium bordering the pilosebaceous canal at infra-infundibulum level then forms a large quantity of abnormally keratinized cells, a large quantity of keratin and a particularly sparingly soluble intercellular ground substance. At infra-infundibulum level, this creates a compact plug which prevents expulsion of the sebum: this is the microcyst or closed comedo stage, the true elementary lesion of acne. The microcyst can then evolve in 2 ways: either the keratin and sebum continue to provoke swelling of the microcyst forcing dilation of the acro-infundibulum, thus forming an open comedo or common blackhead, with no real seriousness; or the wall of the microcyst ruptures with irruption into the dermis of sebum, keratin and free fatty acids. An inflammatory reaction occurs, which is exacerbated by the last component in the etiology of acne.
- Microbial Factor
- Normally, in the pilosebaceous follicle, 3 types of microorganism exist: a yeast: Pityrosporum ovale, whose pathogenic role in acne appears nil, a non-pathogenic white Staphylococcus, an anaerobic bacteria, diphtheroid and Gram-positive: Corynebacterium acnes (formerly called Propionibacterium acnes), which synthesizes a lipase able to hydrolyze the triglycerides of sebum into free fatty acids that are irritants for the dermis. This microorganism is also involved in the local production of protease, hyaluronidase and neuraminidase, which exacerbate the inflammatory process cited above.
- The data presented above are derived from a review of the following documents: F. Poli (1996): Acné prépubertaire, Le Concours Médical, 118:905-908; P. Morel (1981), polycopié de dermato et vénéro, Le Kremlin Bicêtre: 161-179; François Daniel (1977): Dermatologie pratique, Edition Dupuy-Compton Médical, Neuilly. Both during adolescence and adulthood, acne induces a negative self-image in people who have acne-prone skin. The cosmetic industry is thus within its scope when it proposes a new approach to resolving the problems of acne-prone skins.
- The present invention includes the use of oleanolic acid, pure or isolated or contained in titrated olive tree (Olea europaea) leaf extract in an effective and/or sufficient quantity, in a cosmetic or dermopharmaceutical composition. These compositions may be intended to prevent and treat the symptoms of acne, hyperseborrhea and acne-prone skin. The oleanolic acid, whether as part of an extract or otherwise may be used along with an effective and/or sufficient quantity of nordihydroguaiaretic acid (pure or isolated or in the form of a titrated Larrea divaricata extract).
- Cosmetic or dermopharmaceutical compositions intended to prevent and treat the symptoms of acne, hyperseborrhea and to prevent symptoms in acne-prone skin containing an effective and sufficient quantity of oleanolic acid or titrated Olea europaea leaf extract containing it. These cosmetic or dermopharmaceutical compositions may also contain an effective and/or sufficient quantity of nordihydroguaiaretic acid or a titrated Larrea divaricata extract containing it. In a preferred embodiment of these cosmetic or dermopharmaceutical compositions, the quantity of oleanolic acid is between 1 and 10,000 ppm (0.0001 and 1% m/m), preferably between 10 and 1000 ppm (0.001 and 0.1% m/m). The quantity of nordihydroguaiaretic acid is, if present, between 1 and 10,000 ppm (0.0001 and 1% m/m), preferably between 10 and 1000 ppm (0.001 and 0.1% m/m).
- A particularly preferred cosmetic and/or dermopharmaceutical composition includes a concentration of the oleanolic acid (used pure or in the form of Olea europaea extract) of between 5 and 50 ppm (0.0005 to 0.05% m/m) and a concentration of nordihydroguaiaretic acid (used pure or in the form of titrated Larrea divaricata extract) of between 1 and 100 ppm (0.0001 to 0.01% m/m).
- Cosmetic or dermopharmaceutical compositions may include any other ingredient usually employed in the fields of cosmetics and dermopharmacy. These can include, without limitation, lipids including extracted and/or synthetic lipids, gelling and viscosifying polymers, surfactants and emulsifying agents, any water- or fat-soluble active substance, plant extracts of all sorts, synthetic peptides, proteins, vitamins, tissue extracts, marine extracts, sunscreens and antioxidants. A particularly preferred composition includes OSMOCIDE® (marketed by the Sederma company, France). These cosmetic or dermopharmaceutical compositions may be combined with other active substances and may be used in any pharmaceutical form employed in cosmetics or dermopharmacy such as, without limitation, gels, O/W and W/O emulsions, milks, lotions, ointments, scalp lotions, shampoos, soaps, sticks and pencils, sprays and body oils.
- The active substances may be used in the form of a solution, dispersion or emulsion, or encapsulated in carriers such as macro-, micro- or nanocapsules, liposomes or chylomicrons, or included in macro-, micro- or nanoparticles, or in microsponges, or adsorbed on powdered organic polymers, talcs, bentonites and other inorganic carriers.
- Oleanolic acid, pure or in the form of titrated olive tree (Olea europaea) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract), or combined with other active substances can be used for the preparation of a medicinal product used for any form of moisturizing or anti-inflammatory care of the skin and in the prevention and treatment of acne-prone skin.
- The cosmetic or dermopharmaceutical compositions of the invention may have the active substances impregnated on any sort of textile, synthetic or natural fiber, wool or any material liable to be used for the manufacture of clothing or underclothing, active materials of any sort, wipes, patches, compresses, cottons, cotton buds, dressings, makeup-removal sponges, masks and any other carrier liable to come into direct contact with the skin or scalp to enable continuous topical delivery.
- It has been discovered that oleanolic acid and extracts of olive tree (Olea europaea) leaves titrated with respect to oleanolic acid content, are endowed with a strong inhibitory action on the enzyme, 5α-reductase, and thus constitute an important component in the treatment of the symptoms of acne-prone skin. It has also been discovered that oleanolic acid and the extracts of olive tree leaves are endowed with antimicrobial activity against Corynebacterium acnes and Acinetobacter calcoaceticus. The use of oleanolic acid and olive leaf extracts to prevent and treat the symptoms of acne and acne-prone skin is thus new.
- In addition, surprisingly, it has been discovered that a synergy is obtained by combining nordihydroguaiaretic acid or an extract of Larrea divaricata of known nordihydroguaiaretic acid content with oleanolic acid or extracts of olive tree leaves.
- Nordihydroguaiaretic acid is an inhibitor of protein metabolism in the Golgi apparatus and thus plays a moderating role in cell growth. The use of nordihydroguaiaretic acid to slow the growth of the skin and appendages has been described in FR 2785804. It appears that combination of oleanolic acid and nordihydroguaiaretic acid or extracts containing those compounds strengthens the antimicrobial activity and decreases hyperkeratinization concomitantly, thus enhancing prevention of the symptoms of acne.
- Anti-acne activity can be further reinforced if the cosmetic and dermopharmaceutical compositions containing said extracts are formulated with other appropriate compounds such as keratolytic, sebum-regulating, moisturizing and/or osmotic active substances (particularly those with specific antimicrobial and anti-inflammatory activities).
- The other constituents of the compositions may be any habitually or newly used or usable ingredient in cosmetics and dermopharmacy.
- Oleanolic acid combined or not combined with nordihydroguaiaretic acid and/or the plant extracts containing them may thus be advantageously used in the prevention and treatment of acne-prone skin since: oleanolic acid decreases hyperseborrhea by inhibiting 5α-reductase and nordihydroguaiaretic acid (NDGA) exerts an anti-inflammatory and antiproliferative effect on keratinocytes and reduces hyperkeratinization.
- In cosmetic or dermopharmaceutical compositions, it may be advantageous to combine the extracts cited with other active substances in order to strengthen their effect by an additive or synergistic effect of the various products or in order to combine the effect described in this patent application with another beneficial physiological effect for the skin, mucous membranes, cutaneous appendages (hair and scalp), such as OSMOCIDE® (Sederma).
- The oleanolic acid and, possibly, nordihydroguaiaretic acid concentrations in the cosmetic or dermopharmaceutical product may vary from 1 to 10,000 ppm (0.0001 and 1%, m/m), preferably between 10 and 1000 ppm (0.001 and 0.1% m/m). In combination with nordihydroguaiaretic acid, preferably 5 to 50 ppm (0.0005 to 0.05% m/m) of oleanolic acid and 1 to 100 ppm (0.0001 to 0.01% m/m) of nordihydroguaiaretic acid will be used. The concentrations of the more or less crude or purified extracts of olive tree leaves and L. divaricata used in the finished products depend on their respective oleanolic acid and nordihydroguaiaretic acid contents. The final concentrations of the main active substances (oleanolic acid and nordihydroguaiaretic acid) are to lie within the ranges cited.
- Oleanolic acid pure or in the form of titrated olive tree (Olea europaea) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract) or combined with other active substances, may be used in any pharmaceutical form employed in cosmetics or dermopharmacy: O/W and W/O emulsions, milks, lotions, ointments, scalp lotions, shampoos, soaps, sticks and pencils, sprays and body oils, without that list being exhaustive.
- Oleanolic acid pure or in the form of titrated olive tree (Olea europaea) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract), or combined with other active substances, may be used in the form of solutions, dispersions and emulsions, or encapsulated in carriers such as macro-, micro- or nanocapsules and liposomes or chylomicrons, or included in macro-, micro- or nanoparticles or in microsponges, or adsorbed on powdered organic polymers, talcs, bentonites or other inorganic carriers.
- Oleanolic acid pure or in the form of titrated olive tree (Olea europaea) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract) may be combined with any other usually employed ingredient: extracted and/or synthetic lipids, gelling and viscosifying polymers, surfactants and emulsifying agents, all water- and fat-soluble active substances, plant extracts of any sort, synthetic peptides, proteins, vitamins, tissue extracts, marine extracts, sunscreens and antioxidants.
- Oleanolic acid pure or in the form of titrated olive tree (Olea europaea) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract) or combined with other active substances, may be used in cosmetic or dermopharmaceutical compositions for all skin care, moisturizing or anti-inflammatory, and in the prevention and treatment of acne-prone skin.
- Oleanolic acid pure or in the form of titrated olive tree (Olea europaea) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract) or combined with other active substances, may be incorporated in cosmetic compositions or dermopharmaceuticals for the preparation of medicinal products used in moisturizing or anti-inflammatory care of the skin and in the prevention and treatment of acne-prone skin.
- Oleanolic acid, pure or in the form of titrated olive tree (Olea europaea) leaf extract, alone or in combination with nordihydroguaiaretic acid (pure or in the form of titrated Larrea divaricata extract), or combined with other active substances, may be used to impregnate any sort of textile, synthetic or natural fibers, wool or any materials liable to be used for the manufacture of clothing or underclothing, active materials of any sort, wipes, patches, compresses, cottons, and cotton buds, dressings, makeup-removing sponges, masks, or any other carrier liable to come into direct contact with the skin and scalp to enable continuous topical delivery. A more complete list of possible cosmetic compositions and other usually employed ingredients can be found in Robinson et al. U.S. Pat. No. 6,492,326 B1, which issued on Dec. 10, 2002. The text from column 5, line 35 trough column 20, line 52 and column 20, line 61 through column 34, line 11 is hereby incorporated by reference. The text and claims as published of WO 03/028692 published on Apr. 10, 2003 and filed Oct. 1, 2002 as PCT/FR02/03344 are hereby incorporated by reference.
- The following nonlimiting examples are for the purpose of illustrating some of the uses and advantages of certain embodiments of the present invention. Examples 1 to 4 illustrate the various possibilities for compositions intended for cosmetic or dermopharmaceutical uses containing oleanolic acid and/or nordihydroguaiaretic acid or the corresponding extracts.
- Examples 5 to 10 illustrate the effects of those compositions and the synergistic effects observed with combination of the various constituents.
-
Butylene glycol 25.00 Oleanolic acid 0.03 Nordihydroguaiaretic acid 0.04 PEG-60 almond glycerides 10.00 Osmocide ® (Sederma) 64.93 -
Carbopol ® 1342 (Goodrich) 0.3 Propylene glycol 2 Glycerol 1 White soft paraffin 1.5 Cyclomethicone 6 Cetyl alcohol 0.5 Lubrajel ® MS (United Guardian) 10 Triethanolamine 0.3 Oleanolic acid 0.0015 Nordihydroguaiaretic acid 0.002 Osmocide ® (Sederma) 9.0 Water, preservatives, fragrance q.s. 100 g -
Brij ® 721 (ICI) 2.4 Volpo ® S72 (Croda) 2.6 Prostearyl-15 (Croda) 8.0 Beeswax 0.5 Abil ® ZP 2434 (Goldschmidt) 3.0 Propylene glycol 3.0 Carbopol ® 941 (B. F. Goodrich) 0.25 Triethanolamine 0.25 Olea europaea extract 10.0 Larrea divaricata extract 5.0 Osmocide ® (Sederma) 10.0 Water, preservatives, fragrances q.s. 100 g -
Ethanol 1.0 Propylene glycol 2.0 Abil ® B8851 (Goldschmidt) 0.5 Eumulgin ® L (Henkel) 0.6 Oleanolic acid 0.05 Water, preservatives, fragrance q.s. 100 g - Principle and implementation of the test (adapted from Zy and Zu, 1998):
- Testosterone is irreversibly metabolized by 5α-reductase to 5-dehydrotestosterone (5-DHT) in the presence of the cofactor NADPH. The reaction is monitored, at 37° C., by determining, using a spectrophotometer, the reduction in the absorbance of the reaction medium at 340 nm, due to the conversion of NADPH to NADP.
- The test thus consists in mixing testosterone, NADPH and the test product or its vehicle alone (control reaction). After 3 minutes to allow the system to equilibrate, the baseline absorbance of the system is determined. Then the reaction is triggered by addition of the enzyme, 5α-reductase. After 10 minutes, a second determination of the absorbance, final absorbance, is conducted. The difference between the two measurements reflects the quantity of NADPH consumed. That quantity is proportional to the quantity of testosterone converted to 5-DHT.
- Oleanolic acid and nordihydroguaiaretic acid were tested at various concentrations alone or in combination.
- Results: the following table shows the percentage inhibition (mean±SEM) observed in 5 independent assays.
Test product [c] % inhibition Oleanolic acid 0.01% 16.7 ± 1.1% 0.03% 31.7 ± 2.9% 0.1% 56.3 ± 2.6% NDGA 0.01% 2.1 ± 1.6% 0.04% 3.7 ± 2.9% 0.1% 3.0 ± 1.9% Oleanolic acid + 0.03% nordihydroguaiaretic acid 0.04% 68.3 ± 3.1% - These results clearly demonstrate that oleanolic acid has a strong inhibitory activity on the enzyme, 5α-reductase, since, under the above experimental conditions, 56% inhibition was observed with only 0.1%. Moreover, this effect is specific since it is concentration-dependent.
- Nordihydroguaiaretic acid used alone has no activity in this test.
- There is strong synergy between the effects when the 2 products are used in combination, since the inhibition observed (68%) is markedly greater than the sum of the individual effects observed in the same test at the same concentrations, since the sum of the effects is only 35.4%.
- Principle and implementation of the test: the aim of this test was to confirm the previous result but using an HPLC analysis method. Unlike 5-DHT, testosterone absorbs light at the wavelength used (245 nm). The decrease in testosterone peak area (which was characterized under our operating conditions by a retention time of 26 minutes) reflects the reduction of the concentration of the compound in the study medium and thus reflects 5α-reductase activity.
- The same type of protocol as in the previous example was used, but instead of determining the absorbances, the reaction media were analyzed by HPLC.
- Results: the following table shows the percentage inhibition (mean±SEM) observed in 5 independent assays.
Test product [c] % inhibition Oleanolic acid 0.01% 10.9 ± 1.4% (obtained from olive tree 0.03% 25.6 ± 2.0% leaves) 0.1% 47.7 ± 3.8% Nordihydroguiararetic acid 0.01% 1.2 ± 0.4% (obtained from L. divaricata) 0.04% 1.0 ± 0.9% 0.1% 0.9 ± 0.7% Oleanolic acid + 0.03% nordihydroguaiaretic acid 0.04% 61.8 ± 4.2% - The results clearly show that:
- the effects observed in this example are very similar to those observed in the previous example confirming the initial hypothesis;
- oleanolic acid is endowed with strong inhibitory activity vis-à-vis the enzyme, 5α-reductase, since, under our experimental conditions, 48% inhibition was observed with only 0.1% oleanolic acid. Nordihydroguaiaretic acid used alone had no activity in this test;
- there is patent synergy between the effects when the 2 products are used in combination, since the observed inhibition (61.8%) is markedly greater than the sum of the individual effects observed in the same test at the same concentrations, since the sum of the effects is only 26.6%.
- It is possible to estimate a degree of inflammation by determining the quantity of mediators such as prostaglandins, leukotrienes or interleukins.
- In this example, we selected assay of interleukin 6 (IL-6) on normal human fibroblasts (HF) and keratinocytes (HK) in culture following exposure to UV-B irradiation.
- Broadly speaking, the cells were cultured in a conventional culture medium (DMEMc+10% FCS) for periods of 24 hours for HF and 1 week for HK. After elimination of the buffer and 2 successive washings with phosphate buffer solution, the cells were exposed to UV-B irradiation at a standardized energy level of 50 mJ.cm−2.
- The buffer was then rapidly eliminated and replaced by the same culture medium as that used at the start of the experiment, but containing the test extracts at the prerequisite concentrations or DMSO for the control series. After 24 hours, the culture medium was harvested and IL-6 concentration determined using a standard ELISA method.
- An additional series was conducted using the same protocol but without UV-B irradiation in order to determine the baseline level and control the stability of the study system. All the assays were conducted in triplicate.
- The following table shows the results (mean±SEM of the percentage change vs. the tests conducted without UV radiation exposure) for 5 independent assays.
HF HK Test product [c] % change % change Control — +439 ± 11% +450 ± 15% Oleanolic acid 0.01% +455 ± 14% +461 ± 16% 0.03% +437 ± 12% +444 ± 14% 0.1% +441 ± 18% +450 ± 14% NDGA 0.01% +356 ± 18% +388 ± 10% 0.04% +155 ± 9% +201 ± 10% 0.1% +87 ± 7% +91 ± 14% Oleanolic acid + 0.03% nordihydroguaiaretic 0.04% +47 ± 4% +58 ± 4% acid - The results clearly show that:
- nordihydroguaiaretic acid has a remarkable anti-inflammatory effect on the 2 cell lines studied since, under our experimental conditions (HF and HK), inhibition of 19% (+356 vs. +439%) and 14% (+388 vs. +450%) was observed with a nordihydroguaiaretic acid concentration of only 0.01%. Moreover, the effect was specific, since it was concentration-dependent;
- oleanolic acid used alone is devoid of activity in this test;
- for the 2 cell lines, there was patent synergy between the effects when the 2 compounds were used in combination, since 90% inhibition (+47 vs. +439%, HF) and 87% inhibition (+58 vs. +450%, HK), respectively, were observed. These inhibitions were markedly greater than the sum of the individual effects observed in the same test at the same concentrations.
- Test principle and implementation: since the quantity of DNA is constant for each cell, the determination of the overall quantity of DNA is equivalent to measuring the number of cells used for the determination. This principle enables routine use of more refined but very cumbersome methodologies to be avoided. Various methods have been developed on the basis of this protocol, of which, in particular, that used herein. When bound to DNA with a constant and known stereochemistry, the fluorophore, Hoechst 33258, presents, first, increased fluorescence, but also an emission spectrum shift from 492 to 458 nm. By means of comparison with pre-established sets of standards, the concomitant monitoring of the above 2 parameters enables quantification of the quantity of DNA present in the cell samples studied.
- Broadly speaking, normal human keratinocytes (HK) are cultured in a classic culture medium (DMEMc+10% FCS) for 1 week, in the absence of the test product (control series in order to determine the baseline cell proliferation of the system studied) or in the presence of the test products alone or in combination. Fluorophore Hoechst 33258 was added at the end of the protocol before withdrawing cell aliquots for assay. The assays were conducted in triplicate as 3 mutually independent assays.
- Results: the following table shows the percentage inhibition (mean±SEM) with respect to the quantities of DNA (and hence the number of cells present, as observed in each of the 5 independent assays).
Test product [c] % inhibition Oleanolic acid 0.01% 0.9 ± 1.0% 0.03% 1.1 ± 1.6% 0.1% 0.7 ± 0.7% NDGA 0.01% 10.2 ± 1.5% 0.04% 22.3 ± 1.9% 0.1% 29.9 ± 1.7% Oleanolic acid + 0.03% nordihydroguaiaretic acid 0.04% 41.7 ± 3.4% - The results clearly show that:
- nordihydroguaiaretic acid strongly inhibits keratinocyte proliferation since, under our experimental conditions, 10% inhibition was observed with a concentration of only 0.01% nordihydroguaiaretic acid. Moreover, the effect was specific since it was concentration-dependent;
- oleanolic acid used alone was devoid of activity in this test;
- there was a patent synergy between the effects when the 2 compounds were used in combination, since the observed inhibition (41.7%) was markedly greater than the sum of the individual effects observed in the same test at the same concentrations, since the sum was only 23.4%.
- Test principle and implementation: 1 mL of the premix in example No. 1 or its constituents at concentrations equivalent to 5% of the premix were incorporated in molten agar medium (BioMerieux) plated in a Petri dish. The dish was stirred to blend the compound in the agar. 10 μL of study bacteria suspension diluted to contain approximately 104 and 105 bacteria/mL was applied to the solid agar at room temperature. The plates were then incubated at 37° C. for 24 and 48 hours and inspected visually.
- Five strains, Corynebacterium minutissimum, Propionibacterium acnes, Staphylococcus aureus, Staphylococcus hominis and Acinetobacterium calcoaceticus were studied.
- Results: The following table shows the observed antimicrobial activity results for the constituents and their combination in the cosmetic excipient.
- Oleanolic acid exerted selective antimicrobial activity against the microorganisms P. acnes and A. calcoaceticus. Nordihydroguaiaretic acid exerted selective antimicrobial activity against A. calcoaceticus and S. hominis. OSMOCIDE® exerted selective antimicrobial activity against S. aureus, S. hominis and P. acnes, while none of the other constituents showed any effect.
- The combination of the constituents in the premix in example 1 showed the most complete antimicrobial activity, inactivating all the test microorganisms.
- The strains studied are shown in the table as:
- Strain A: Corynebacterium minutissimum
- Strain B: Staphylococcus hominis
- Strain C: Staphylococcus aureus
- Strain D: P. acnes
- Strain E: Acinetobacterium calcoaceticus
Strains studied A B C D E Bacteria/mL 105 104 105 104 105 104 105 104 105 104 Butylene glycol + + + + + + + − − − − oleanolic acid + + − − + + + − − − Butylene glycol + + + + + + + + + + + nordihydroguaiaretic + + − − − − − − + + acid + + + + + + + + + + Butylene glycol + − − − − − − − − − − water OSMOCIDE − − − − − − − − − − PEG-60 almond oil + water 5% premix No. 1 Trichlosan (reference substance)
The results at 24 h (above) were the same as those observed at 48 h.
Key:
‘+’ = bacterial growth,
‘−’ = no bacterial growth
- The study was conducted in 30 volunteers, with equal numbers of both genders, aged 14 to 20 years, selected for their acne-prone skin, i.e. presenting with at least 2 inflammatory lesions (papules, pustules, nodules) and/or 10 retentive lesions (comedo and microcyst).
- The test product, the gel in example No. 2, was applied for 2 months, morning and night, after conventional cleansing of the skin. All other products (topical medication, cosmetic or dermatological products) were prohibited throughout the duration of the study.
- The lesions were counted and observed by dermatologists, on the same predetermined area of the facial skin (20 cm2), pre-treatment (T0) and after 30 (T30) and 60 (T60) days of treatment. A significant decrease in the lesions and a marked improvement in the state of the face were observed after the cosmetic treatment. The product did not induce irritation, edema or other signs of poor tolerance.
Claims (23)
1. A method of treating acne-prone skin comprising the steps of providing a cosmetic or dermopharmaceutical composition comprising an effective quantity of oleanolic acid, wherein said effective quantity is between about 1 ppm and about 10,000 ppm, and applying said composition to skin in need thereof.
2. The method of claim 1 , wherein said effective quantity of oleanolic acid is between about 10 ppm and about 1,000 ppm.
3. The method of claim 1 , wherein said composition further comprises nordihydroguaiaretic acid.
4. The method of claim 3 , wherein said nordihydroguaiaretic acid is between about 1 and about 10,000 ppm.
5. The method of claim 1 , wherein said composition further comprises at least one other ingredient employed in the treatment of acne, hyperseborrhea and acne-prone skin.
6. The method of claim 5 , wherein said at least one other ingredient employed in the treatment of acne, hyperseborrhea and acne-prone skin is selected from the group consisting of keratolytic, sebum-regulating, moisturizing and osmotic active substances.
7. A method of treating skin inflammation in the skin of a subject in need thereof comprising the steps of providing a cosmetic or dermopharmaceutical composition comprising an effective quantity of oleanolic acid, wherein said effective quantity is between about 1 ppm and about 10,000 ppm, and applying said composition to skin in need thereof.
8. The method of claim 7 , wherein said effective quantity of oleanolic acid is between about 10 ppm and about 1,000 ppm.
9. The method of claim 7 , wherein said composition further comprises nordihydroguaiaretic acid.
10. The method of claim 9 , wherein said nordihydroguaiaretic acid is between about 1 and about 10,000 ppm.
11. The method of claim 7 , wherein said composition further comprises at least one other ingredient employed in the treatment of acne, hyperseborrhea and acne-prone skin.
12. The method of claim 11 , wherein said at least one other ingredient employed in the treatment of acne, hyperseborrhea and acne-prone skin is selected from the group consisting of keratolytic, sebum-regulating, moisturizing and osmotic active substances.
13. A method of treating or preventing symptoms of acne or hyperseborrhea comprising the steps of providing a cosmetic or dermopharmaceutical composition comprising an effective quantity of oleanolic acid, wherein said effective quantity is between about 1 ppm and about 10,000 ppm, and optionally nordihydroguaiaretic, and applying said composition to skin in need thereof.
14. The method of claim 13 , wherein said effective quantity of oleanolic acid is between about 10 ppm and about 1,000 ppm.
15. The method of claim 13 , wherein said nordihydroguaiaretic acid is between about 1 ppm and about 10,000 ppm.
16. The method of claim 13 , wherein said composition further comprises at least one other ingredient employed in the treatment of acne, hyperseborrhea and acne-prone skin.
17. The method of claim 16 , wherein said at least one other ingredient employed in the treatment of acne, hyperseborrhea and acne-prone skin is selected from the group consisting of keratolytic, sebum-regulating, moisturizing and osmotic active substances.
18. A method of reducing 5a-reductase in the skin of a subject in need thereof comprising the steps of providing a cosmetic or dermopharmaceutical composition comprising an effective quantity of oleanolic acid, wherein said effective quantity is between about 1 ppm and about 10,000 ppm, and administering said an amount of said composition to a portion of said skin of said subject sufficient to reduce the levels of 5α-reductase in said skin of said subject.
19. The method of claim 18 , wherein said effective quantity of oleanolic acid is between about 10 ppm and about 1,000 ppm.
20. The method of claim 18 , wherein said composition further comprises nordihydroguaiaretic acid.
21. The method of claim 20 , wherein said nordihydroguaiaretic acid is between about 1 and about 10,000 ppm.
22. The method of claim 18 , wherein said composition further comprises at least one other ingredient employed in the treatment of acne, hyperseborrhea and acne-prone skin.
23. The method of claim 22 , wherein said at least one other ingredient employed in the treatment of acne, hyperseborrhea and acne-prone skin is selected from the group consisting of keratolytic, sebum-regulating, moisturizing and osmotic active substances.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/390,710 US20060239957A1 (en) | 2001-10-03 | 2006-03-28 | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/12802 | 2001-10-03 | ||
FR0112802A FR2830195B1 (en) | 2001-10-03 | 2001-10-03 | COSMETIC AND DERMOPHARMACEUTICAL COMPOSITIONS FOR SKINS WITH ACNE TREND |
PCT/FR2002/003344 WO2003028692A2 (en) | 2001-10-03 | 2002-10-01 | Acne treatment using oleanolic acid |
US10/817,670 US7182963B2 (en) | 2001-10-03 | 2004-04-02 | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
US11/390,710 US20060239957A1 (en) | 2001-10-03 | 2006-03-28 | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/817,670 Division US7182963B2 (en) | 2001-10-03 | 2004-04-02 | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060239957A1 true US20060239957A1 (en) | 2006-10-26 |
Family
ID=8867942
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/817,670 Expired - Lifetime US7182963B2 (en) | 2001-10-03 | 2004-04-02 | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
US11/390,710 Abandoned US20060239957A1 (en) | 2001-10-03 | 2006-03-28 | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/817,670 Expired - Lifetime US7182963B2 (en) | 2001-10-03 | 2004-04-02 | Cosmetic and dermopharmaceutical compositions for skin prone to acne |
Country Status (8)
Country | Link |
---|---|
US (2) | US7182963B2 (en) |
EP (1) | EP1438015B1 (en) |
JP (1) | JP2003113069A (en) |
AU (1) | AU2002362482A1 (en) |
DE (1) | DE60237221D1 (en) |
ES (1) | ES2348278T3 (en) |
FR (1) | FR2830195B1 (en) |
WO (1) | WO2003028692A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213198A1 (en) * | 2004-04-26 | 2008-09-04 | Sederma Sas | Cosmetic or Dermopharmaceutical Composition Comprising at Least one Udp Glucuronosyl Transferase (Ugt) Enzymes Inducer |
US20090010976A1 (en) * | 2002-07-30 | 2009-01-08 | Sederma | Cosmetic or dermopharmaceutical compositions containing kombucha |
US20090017147A1 (en) * | 2005-01-14 | 2009-01-15 | Sederma | Cosmetic or Dermopharmaceutical Composition Comprising an Euglena Extract |
US20090214607A1 (en) * | 2005-05-13 | 2009-08-27 | Sederma | Topical use of teprenone |
US20090253666A1 (en) * | 2006-08-03 | 2009-10-08 | Sederma | Composition comprising sarsasapogenin |
WO2010079914A2 (en) * | 2009-01-06 | 2010-07-15 | Industry-Academic Coorperation Foundation Daegu Haany University | A composition comprising the compound isolated from the extract of rubiae radix for preventing and treating inflammatory diseases |
US20110045036A1 (en) * | 2006-05-05 | 2011-02-24 | Sederma | Cosmetic Compositions Comprising at Least One Peptide with at Least One Immobilized Aromatic Cycle |
US8846019B2 (en) | 2005-09-06 | 2014-09-30 | Sederma | Use of protoberberines as an active substance regulating the pilosebaceous unit |
WO2015002960A1 (en) * | 2013-07-02 | 2015-01-08 | Memorial Sloan Kettering Cancer Center | Apparatus, arrangement and method for providing skin care ingredients |
WO2014041542A3 (en) * | 2012-09-13 | 2015-07-23 | Kamedis Ltd | Topical compositions for the treatment of acne |
US10968027B2 (en) | 2013-07-02 | 2021-04-06 | Memorial Sloan-Kettering Cancer Center | Apparatus, arrangement and method for providing skin care ingredients |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2371026T3 (en) | 2001-10-19 | 2011-12-26 | Atritech, Inc. | ADJUSTABLE OCLUSION DEVICE IN THE LEFT HEADPHONE OREJUELA. |
DE10213019A1 (en) * | 2002-03-22 | 2003-10-02 | Cognis Deutschland Gmbh | Use of extracts from the olive tree as an antidandruff agent |
FR2859104A1 (en) * | 2003-08-29 | 2005-03-04 | Saint Laurent Parfums | MOLECULES WITH ANTI-ADIPOGENIC ACTIVITY ON HUMAN ADIPOCYTE CELLS |
CN1893911B (en) | 2003-11-17 | 2010-12-29 | 赛德玛公司 | Formula including tetrapeptide and tripeptide mixture |
KR100567431B1 (en) * | 2004-01-08 | 2006-04-04 | 황재관 | Composition Containing Lignan Compounds for Preventing or Treating of Acne |
JP4822704B2 (en) * | 2004-12-28 | 2011-11-24 | ユニ・チャーム株式会社 | Cleaning tool |
DE102005030460A1 (en) * | 2005-06-28 | 2007-01-04 | Henkel Kgaa | Agent for the treatment of hair or skin containing an extract of plants belonging to the family Oleaceae |
ES2267402B1 (en) * | 2005-08-17 | 2008-03-16 | Universidad De Granada | FORMULATION OF NATURAL TRITERPENES OBTAINED FROM OLEA GENDER IN LIPOSOMAS. |
FR2894465B1 (en) * | 2005-12-14 | 2010-09-10 | Fabre Pierre Dermo Cosmetique | USE OF POLYUNSATURATED COMPOUNDS AS BLANCHING AGENTS |
US8404648B2 (en) | 2006-02-16 | 2013-03-26 | Sederma | Polypeptides KXK and their use |
EP1844785A1 (en) * | 2006-04-13 | 2007-10-17 | Indena S.P.A. | Phospholipid complexes of olive fruits or leaves extracts having improved bioavailability |
ES2286953B1 (en) * | 2006-05-18 | 2008-12-16 | Universidad De Granada | FORMULATION OF NATURAL TRITERPENES AND BIOPHENOLS OBTAINED FROM THE OLEA GENDER IN LIPOSOMAS. |
JP2009143897A (en) * | 2007-11-19 | 2009-07-02 | Neochemir Inc | Therapeutic agent for pimple |
US9445975B2 (en) * | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
FR2939799B1 (en) | 2008-12-11 | 2011-03-11 | Sederma Sa | COSMETIC COMPOSITION COMPRISING ACETYL OLIGOGLUCURONANS. |
FR2941232B1 (en) | 2009-01-16 | 2014-08-08 | Sederma Sa | NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES |
FR2941231B1 (en) | 2009-01-16 | 2016-04-01 | Sederma Sa | NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES |
EP2382231A2 (en) | 2009-01-16 | 2011-11-02 | Sederma | New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses |
FR2944435B1 (en) | 2009-04-17 | 2011-05-27 | Sederma Sa | COSMETIC COMPOSITION COMPRISING ORIDONIN |
FR2945939B1 (en) | 2009-05-26 | 2011-07-15 | Sederma Sa | COSMETIC USE OF TYR-ARG DIPEPTIDE TO FIGHT SKIN RELEASE. |
FR2970868B1 (en) | 2011-01-31 | 2023-10-27 | Sederma Sa | EXTRACT OF PLANT ORIGIN, COMPOSITION CONTAINING IT, METHOD OF OBTAINING BY PLANT CULTURE AND USES IN THE COSMETIC, PHARMACEUTICAL AND COSMECEUTICAL FIELDS |
FR2975904B1 (en) | 2011-06-01 | 2013-08-23 | Sederma Sa | NOVEL TOP USE, COSMETIC OR DERMOPHARMACEUTICAL, OF A MIXTURE COMPRISING A GHK TYPE TRIPEPTIDE AND A GQPR TYPE TETRAPEPTIDE |
FR2978351B1 (en) | 2011-07-28 | 2014-02-21 | Sederma Sa | PLANT ORIGINAL MATERIAL, COMPOSITION CONTAINING SAME, AND TOPICAL COSMETIC USE |
FR2985424B1 (en) | 2012-01-10 | 2019-03-29 | Sederma | NEW TOPICAL USE OF ZERUMBON |
FR2997299B1 (en) | 2012-10-30 | 2014-12-26 | Sederma Sa | ASSOCIATION OF PLANT EXTRACTS, COSMETIC ACTIVE INGREDIENT AND COMPOSITION CONTAINING THE SAME, AND COSMETIC TOPICAL USE |
US9023399B2 (en) * | 2012-11-16 | 2015-05-05 | NU Technology, LLC | Water-soluble anti-inflammatory cream with natural ingredients base |
FR3024037B1 (en) | 2014-07-25 | 2018-03-02 | Sederma | COSMETIC OR DERMATOLOGICAL ACTIVE INGREDIENT COMPRISING A MIXTURE OF UNSATURATED FATTY DICARBOXYLIC ACIDS, COMPOSITIONS COMPRISING THE SAME, AND COSMETIC OR DERMATOLOGICAL USES |
FR3034314B1 (en) | 2015-03-30 | 2019-10-04 | Sederma | TOPICAL COSMETIC TREATMENT OF SKIN AND SCALP LEATHER AND CORRESPONDING ACTIVE INGREDIENT BASED ON AN EXTRACT FROM APIUM GRAVEOLENS |
JP2018058800A (en) * | 2016-10-07 | 2018-04-12 | 国立大学法人九州大学 | Melanin inhibitor |
KR101879193B1 (en) * | 2017-12-18 | 2018-08-17 | (주)아미드팩토리 | Cosmetic Composition For Regenerating skin |
CN111588682A (en) * | 2020-05-28 | 2020-08-28 | 广州百媚化妆品有限公司 | Skin care composition for balancing skin micro-ecology |
JPWO2022014660A1 (en) * | 2020-07-16 | 2022-01-20 | ||
CN112569152B (en) * | 2020-12-22 | 2022-08-23 | 山东花物堂生物科技有限公司 | Oil-control anti-inflammatory plant combined extract and preparation method and application thereof |
AU2021421391A1 (en) | 2021-01-24 | 2023-07-20 | Michael David FORREST | Inhibitors of atp synthase - cosmetic and therapeutic uses |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723139A (en) * | 1996-09-27 | 1998-03-03 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing a polycyclic triterpene carboxylic acid and a retinoid |
US6238678B1 (en) * | 1995-11-06 | 2001-05-29 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
US20010029266A1 (en) * | 1999-12-10 | 2001-10-11 | L'oreal | Composition containing a pentacyclic triterpenic acid, method |
US20020176903A1 (en) * | 1999-10-14 | 2002-11-28 | Noriyasu Kuno | Skin-beautifying agent, anti-aging agent for the skin, whitening agent and external agent for the skin |
US6492326B1 (en) * | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US20030087789A1 (en) * | 2000-03-28 | 2003-05-08 | Scheffler Armin | Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008294A (en) * | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
JPH04173739A (en) * | 1990-11-08 | 1992-06-22 | Nippon Saafuakutanto Kogyo Kk | Beat saponin-containing composition |
JP3586321B2 (en) * | 1995-10-25 | 2004-11-10 | 日本製粉株式会社 | Cosmetics |
FR2785804B1 (en) * | 1998-11-17 | 2002-10-18 | Sederma Sa | COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING LARREA DIVARICATA OR LARREA TRIDENTATA EXTRACT FOR SLOWING SKIN AGING |
WO2001017523A1 (en) * | 1999-09-10 | 2001-03-15 | Applied Genetics Incorporated Dermatics | Compositions and methods for modification of skin lipid content |
DE10015353A1 (en) * | 2000-03-28 | 2001-10-18 | Birken Gmbh | Recovery of pure terpenes from plants, for use as pharmaceutical or cosmetic active agents, by extracting with solvent at elevated pressure and temperature then cooling and depressurizing to induce crystallization |
-
2001
- 2001-10-03 FR FR0112802A patent/FR2830195B1/en not_active Expired - Lifetime
-
2002
- 2002-07-16 JP JP2002207076A patent/JP2003113069A/en active Pending
- 2002-10-01 ES ES02800172T patent/ES2348278T3/en not_active Expired - Lifetime
- 2002-10-01 AU AU2002362482A patent/AU2002362482A1/en not_active Abandoned
- 2002-10-01 DE DE60237221T patent/DE60237221D1/en not_active Expired - Lifetime
- 2002-10-01 EP EP02800172A patent/EP1438015B1/en not_active Expired - Lifetime
- 2002-10-01 WO PCT/FR2002/003344 patent/WO2003028692A2/en not_active Application Discontinuation
-
2004
- 2004-04-02 US US10/817,670 patent/US7182963B2/en not_active Expired - Lifetime
-
2006
- 2006-03-28 US US11/390,710 patent/US20060239957A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6238678B1 (en) * | 1995-11-06 | 2001-05-29 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
US5723139A (en) * | 1996-09-27 | 1998-03-03 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing a polycyclic triterpene carboxylic acid and a retinoid |
US6492326B1 (en) * | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US20020176903A1 (en) * | 1999-10-14 | 2002-11-28 | Noriyasu Kuno | Skin-beautifying agent, anti-aging agent for the skin, whitening agent and external agent for the skin |
US20010029266A1 (en) * | 1999-12-10 | 2001-10-11 | L'oreal | Composition containing a pentacyclic triterpenic acid, method |
US20030087789A1 (en) * | 2000-03-28 | 2003-05-08 | Scheffler Armin | Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090010976A1 (en) * | 2002-07-30 | 2009-01-08 | Sederma | Cosmetic or dermopharmaceutical compositions containing kombucha |
US20080213198A1 (en) * | 2004-04-26 | 2008-09-04 | Sederma Sas | Cosmetic or Dermopharmaceutical Composition Comprising at Least one Udp Glucuronosyl Transferase (Ugt) Enzymes Inducer |
US8530426B2 (en) | 2004-04-26 | 2013-09-10 | Sederma Sas | Cosmetic or dermopharmaceutical composition comprising at least one UDP glucuronosyl transferase (UGT) enzymes inducer |
US8741357B2 (en) | 2005-01-14 | 2014-06-03 | Sederma Sas | Cosmetic or dermopharmaceutical composition comprising an euglena extract |
US20090017147A1 (en) * | 2005-01-14 | 2009-01-15 | Sederma | Cosmetic or Dermopharmaceutical Composition Comprising an Euglena Extract |
US20090214607A1 (en) * | 2005-05-13 | 2009-08-27 | Sederma | Topical use of teprenone |
US8846019B2 (en) | 2005-09-06 | 2014-09-30 | Sederma | Use of protoberberines as an active substance regulating the pilosebaceous unit |
US20110045036A1 (en) * | 2006-05-05 | 2011-02-24 | Sederma | Cosmetic Compositions Comprising at Least One Peptide with at Least One Immobilized Aromatic Cycle |
US8507649B2 (en) | 2006-05-05 | 2013-08-13 | Sederma | Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle |
US20090253666A1 (en) * | 2006-08-03 | 2009-10-08 | Sederma | Composition comprising sarsasapogenin |
US8361516B2 (en) | 2006-08-03 | 2013-01-29 | Sederma | Composition comprising sarsasapogenin |
WO2010079914A2 (en) * | 2009-01-06 | 2010-07-15 | Industry-Academic Coorperation Foundation Daegu Haany University | A composition comprising the compound isolated from the extract of rubiae radix for preventing and treating inflammatory diseases |
WO2010079914A3 (en) * | 2009-01-06 | 2010-10-07 | Industry-Academic Coorperation Foundation Daegu Haany University | A composition comprising the compound isolated from the extract of rubiae radix for preventing and treating inflammatory diseases |
WO2014041542A3 (en) * | 2012-09-13 | 2015-07-23 | Kamedis Ltd | Topical compositions for the treatment of acne |
WO2015002960A1 (en) * | 2013-07-02 | 2015-01-08 | Memorial Sloan Kettering Cancer Center | Apparatus, arrangement and method for providing skin care ingredients |
CN105452126A (en) * | 2013-07-02 | 2016-03-30 | 纪念斯隆-凯特林癌症中心 | Apparatus, arrangement and method for providing skin care ingredients |
US10214339B2 (en) | 2013-07-02 | 2019-02-26 | Memorial Sloan-Kettering Cancer Center | Apparatus, arrangement and method for providing skin care ingredients |
CN110406805A (en) * | 2013-07-02 | 2019-11-05 | 纪念斯隆-凯特林癌症中心 | For providing the unit and method of skin caring ingredient |
US10968027B2 (en) | 2013-07-02 | 2021-04-06 | Memorial Sloan-Kettering Cancer Center | Apparatus, arrangement and method for providing skin care ingredients |
US11661259B2 (en) | 2013-07-02 | 2023-05-30 | Memorial Sloan-Kettering Cancer Center | Apparatus, arrangement and method for providing skin care ingredients |
Also Published As
Publication number | Publication date |
---|---|
AU2002362482A1 (en) | 2003-04-14 |
US20040254245A1 (en) | 2004-12-16 |
FR2830195A1 (en) | 2003-04-04 |
WO2003028692A8 (en) | 2004-04-01 |
AU2002362482A8 (en) | 2005-10-27 |
JP2003113069A (en) | 2003-04-18 |
EP1438015A2 (en) | 2004-07-21 |
FR2830195B1 (en) | 2004-10-22 |
ES2348278T3 (en) | 2010-12-02 |
EP1438015B1 (en) | 2010-08-04 |
DE60237221D1 (en) | 2010-09-16 |
WO2003028692A2 (en) | 2003-04-10 |
WO2003028692A3 (en) | 2003-10-02 |
US7182963B2 (en) | 2007-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7182963B2 (en) | Cosmetic and dermopharmaceutical compositions for skin prone to acne | |
US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
US6040347A (en) | Treatment of seborrhoea/cutaneous disorders with octoxyglycerol | |
US5124313A (en) | Methods of improved skin care and the treatment of dermatological conditions | |
KR101018352B1 (en) | Composition of comprising bee-venoms for treating acne | |
US6387947B1 (en) | Antimicrobial cosmetic compositions | |
KR100541271B1 (en) | Antimicrobial compositions for topical use | |
Lee et al. | Comparison of objective and sensory skin irritations of several cosmetic preservatives | |
US20190269747A1 (en) | Synergistic herbal compositions with prebiotic properties for treatment of acne | |
CN1795926B (en) | Pharamaceutical use for treating skin conditions | |
WO2014041542A2 (en) | Topical compositions for the treatment of acne | |
US20040191206A1 (en) | Methods for reduction of inflammation and erythema | |
KR101106690B1 (en) | A composition for anti-sebum and acne-remedy cosmetics | |
KR100879094B1 (en) | Cosmetics formulation containing natural essential oils and its hydrosols | |
CN115337211B (en) | Mild hyposensitization moisturizing acne-removing gel and preparation method thereof | |
KR20060092333A (en) | Cosmetics composition comprising sanguinarin for preventing acne | |
KR20050026401A (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
KR19990039050A (en) | Acne prevention and treatment containing wasp venom extract | |
EP1080719A2 (en) | Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids | |
KR19990055304A (en) | 5α-reductase activity inhibiting composition containing cloves | |
KR101128477B1 (en) | Cosmetic Composition for Acne Improvement and Method for Preparing Therof | |
Dharmik et al. | Anti-Acne Activity of Toothpaste–An Emerging Pimple Treatment | |
CN114948805A (en) | Antibacterial composition containing sweet wormwood herb volatile oil and application of antibacterial composition in acne-removing skin care product | |
JPH0238565B2 (en) | ||
KR20030084484A (en) | Cosmetic compositions for acne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |